Genoptix Acquisition Bolsters Novartis' Companion Dx Efforts for Hematology, NSCLC, CRC

The acquisition, announced Jan. 24, "complements the Novartis internal capabilities aimed at improving health outcomes by advancing individualized treatment programs," Novartis said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.